Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
SPRY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.55 - $18.51
Previous CloseN/A
Volume456.05K
Average Volume (3M)1.31M
Market Cap
$1.42B
Enterprise Value$1.32B
Total Cash (Recent Filing)$275.73M
Total Debt (Recent Filing)$73.00K
Price to Earnings (P/E)174.1
Beta1.59
Next Earnings
Aug 06, 2025EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding98,213,560
10 Day Avg. Volume1,268,540
30 Day Avg. Volume1,313,047
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)5.92
Price to Sales (P/S)0.00
P/FCF Ratio-64.47
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue6.96
Enterprise Value/Gross Profit13.86
Enterprise Value/Ebitda-9.05
Forecast
1Y Price Target
$29.50Price Target Upside113.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
ARS Pharmaceuticals News
PremiumCompany Announcements
Ars Pharmaceuticals’ Neffy Launch Boosts Market Prospects
PremiumCompany Announcements
ARS Pharmaceuticals Reports Strong Q1 2025 Performance
Bulls Say, Bears Say
Bulls Say
Market ExpansionARS Pharmaceuticals' new commercial partnership with ALK is expected to strengthen their financial position with a $145M upfront payment, aiding in the US launch efforts for neffy.
Pediatric Market ExpansionRecent 1 mg neffy pediatric-dose approval and launch significantly expands the addressable market as ~23% of epi prescriptions are in the 15-30 kg weight class.
Product DifferentiationNeffy’s longer shelf life and smaller form factor offer additional differentiation over currently available treatments that will drive both conversion of market share and expansion of the total epinephrine market in the United States.
Bears Say
Operating ExpensesOperating expenses guidance for fiscal year 2025 is expected to increase, although management emphasized that cash flow should not be impacted.
Revenue ExpectationsARS reported net product revenues for neffy of $7.8 million, slightly below consensus from Visible Alpha of $8.0 million.
Ownership Overview
70.37% Insiders
10.48% Mutual Funds
0.02% Other Institutional Investors
11.20% Public Companies and Individual Investors
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $7.55 and its highest was $18.51 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
ARS Pharmaceuticals’s market cap is $1.42B.
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is Aug 06, 2025 which is in 61 days.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on May 14, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.338 by -$0.012.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Undervalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -0.47.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 98,213,560 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.338. Following the earnings report the stock price went down -9.363%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Currently, no hedge funds are holding shares in SPRY
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.50 (113.46% Upside)
$29.50 (113.46% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 525.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 10.1%
Last 30 Days ▲ 10.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.73%
12-Months-Change
Fundamentals
Return on Equity
-6.91%
Trailing 12-Months
Asset Growth
43.82%
Trailing 12-Months
Company Description
ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
SPRY Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong market entry for Neffy with notable revenue growth and expanded insurance coverage. Strategic collaborations and a focus on pediatric dosing are positive, but high operating expenses and a net loss remain challenges. Prior authorization requirements continue to be a barrier, although they are decreasing.Read More>SPRY Stock 12 Month Forecast
Average Price Target
$29.50
▲(113.46%Upside)
Technical Analysis
Mesoblast
―
Immunocore Holdings
―
Edgewise Therapeutics
―
Vera Therapeutics
―
CG Oncology, Inc.
―